Clinical Trial Update: Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and immunogenicity of the rDEN3Δ30 live attenuated dengue vaccine completed, providing initial human safety and imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• rDEN3Δ30 (Live attenuated dengue virus vaccine (rDEN3Δ30))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED